Contents

1 Background and Scope of the Book 1
1.1 Cancer Concepts 1
1.2 Treatment Concepts 2
1.3 Book Structure 3
1.4 Mathematical Models 4
References 5

Part I Treatment of Cancer with Small Molecule Inhibitors

2 An Introduction to Small Molecule Inhibitors and Chronic Myeloid Leukemia 11
2.1 Basics 11
2.2 Natural History of CML 12
2.3 Therapy 13
2.4 The Role of Mathematical Models 15
References 16

3 Basic Dynamics of Chronic Myeloid Leukemia During Imatinib Treatment 19
3.1 Introduction 19
3.2 Basic Hypothesis: Differentiated Versus Stem Cells 20
3.3 Active Versus Quiescent Tumor Stem Cells 21
3.4 Heterogeneity and Correlations in the Bi-Phasic Decline of BCR-ABL Transcript Levels 24
3.5 Role of Immunity and Resistance in Driving Treatment Dynamics 25
3.6 Possible Role of Immune Stimulation for Long-Term Remission 31
3.7 Summary 31
References 32

4 Stochastic Modeling of Cellular Growth, Treatment, and Resistance Generation 35
4.1 Introduction 35
4.2 The Basic Model of Cancer Growth and Generation of Mutations 36
4.2.1 The Concept: A Birth–Death Process with Mutations 36
4.2.2 Stochastic Description: The Example of One Drug . . . 39
4.2.3 The Generating Function Description 40
4.2.4 Treatment Stages and the Method of Characteristics 42
4.2.5 Probability of Extinction and Treatment Success 43
4.2.6 Symmetric Coefficients 45
4.3 Example: The Case of Two Drugs 45
4.3.1 Equations for the Moments 46
4.3.2 Equations for the Characteristics 47
4.4 Mutant Production Before and During Treatment 48
4.4.1 General Theory 48
4.4.2 The Case of One Drug 50
4.4.3 The Case of Two Drugs 53
4.5 Probability of Treatment Success 54
4.5.1 Analytical Results 54
4.5.2 Threshold Tumor Size 55
References 56

5 Evolutionary Dynamics of Drug Resistant Mutants in Targeted Treatment of CML 59
5.1 Introduction 59
5.2 The Conceptual Framework 61
5.3 Evolution of Resistance Against a Single Drug 62
5.4 Evolution of Resistance Against Two or More Drugs 64
5.5 Summary: Evolutionary Dynamics of Resistance 65
5.6 Prevention of Resistance 65
5.7 Application: CML 68
5.8 Model Extension and Applicability 69
5.9 Summary 70
References 71

6 Effect of Cellular Quiescence on the Evolution of Drug Resistance in CML 73
6.1 Introduction 73
6.2 Modeling Resistance Generation in the Context of Quiescence 74

6.3 Methodology 74
6.3.1 The Basic Formalism of Quiescence 74
6.3.2 Modeling Resistance to Drugs in a Population with Quiescence: A Stochastic Approach. 75
6.3.3 Resistance Generation: A Deterministic Approach . . . 77
6.4 Basic Evolutionary Dynamics: Growth Versus Treatment Phase 81
6.5 Quiescence and the Evolution of Resistance 81
6.5.1 Probability of One-Drug Treatment Failure (Due to Resistance) is Independent of Quiescence . . . 82
6.5.2 The Number of Cycling One-Hit Mutants is Independent of the Quiescence Parameters 84
6.5.3 The More Quiescence There is in the Colony, the Smaller is the Total Number of Cycling Wild-Type Cells. 85
6.5.4 The Probability of Two-Drug Treatment Failure (Due to Resistance) Increases with the Quiescence Rate 85
6.5.5 Generalizations. 86
6.6 Cell Death and Mutant Generation: A Comparison. 86
6.6.1 The Probability of Pre-Existence of One-Hit Resistant Mutants is Independent of the Death Rate 87
6.6.2 The Probability of Pre-Existence of Two-Hit Resistant Mutants Increases with the Death Rate 87
6.7 Summary. 88
References 88

7 Combination Therapies: Short-Term Versus Long-Term Strategies 89
7.1 Introduction 89
7.2 Methodology 90
7.2.1 Stochastic Methods. 91
7.2.2 Deterministic Methods 93
7.3 The Models 96
7.4 The Number of Drugs Needed for One-Stage Combination Treatment. 98
7.5 The Size at Which the Number of Drugs can be Reduced. . . . 98
7.6 The Role of the Tumor Size and the Kinetic Rates. 100
7.7 Drugs with Different Specificity and Potency 101
7.7.1 The Drug with a Narrower Activity is More Potent 103
7.7.2 The Drug with a Narrower Activity is Less Potent . . . 104
7.8 Summary. 105
References 105

8 Cross Resistance: Treatment and Modeling 107
8.1 Introduction 107
8.2 The Problem of Cross-Resistance in CML 108
8.3 Methodology 110
8.4 Combination Treatment in the Presence of Cross-Resistance 111
8.5 Summary 115
References 116

9 Mathematical Modeling of Cyclic Cancer Treatments 119
9.1 Introduction 119
9.2 Methodology 120
9.2.1 Deterministic Modeling of Cyclic Treatments 121
9.2.2 Stochastic Modeling of Cyclic Treatments 125
9.3 Mutually Strong Drugs and Treatment Optimization 126
9.3.1 Modeling Cyclic Treatment Strategies: Drug Potencies and Activity Spectra 126
9.3.2 A Prerequisite of Success: Mutually Strong Drugs . . . 127
9.4 Analysis of Drug Treatments with Mutually Strong Drugs 129
9.5 Protocols Involving Drugs of High Toxicity 132
9.6 Summary 135
References 136

Part II Treatment of Cancer with Oncolytic Viruses

10 Introduction to Oncolytic Viruses 139
10.1 What Are Oncolytic Viruses? An Overview 139
10.2 Mathematical Models 141
10.3 Virus Dynamics 142
10.4 Scope 143
References 144

11 Basic Dynamics of Oncolytic Viruses 147
11.1 Introduction 147
11.2 The Model 148
11.3 Nonreplicating Viruses 150
11.4 Replicating Viruses 151
11.5 Evaluation of Replicating Viruses in Culture 153
11.6 Implications for Interpreting Data 153
11.7 Summary 155
References 156

12 Mitotic Virus Transmission and Immune Responses 157
12.1 Introduction 157
12.2 Effect of Mitotic or Vertical Transmission of the Virus 158
12.3 Effect of Virus-Specific CTL 162
12.4 Virus Infection and the Induction of Tumor-Specific CTL 165
12.5 Interactions Between Virus- and Tumor-Specific CTL 168
12.6 Summary 170
References 170

13 Axiomatic Approaches to Oncolytic Virus Modeling 171
13.1 Introduction 171
13.2 The Modeling Framework 172
13.3 Methodology 174
13.3.1 Axiomatic Model Construction 174
13.3.2 The Number of Equilibria 175
13.3.3 Fast Virus Spread 176
13.3.4 Slow Virus Spread 177
13.3.5 Finite Tumor Size 178
13.3.6 Stability 179
13.4 Different Classes of Infection Terms and Their Properties 181
13.5 Effect of the Tumor Growth Term 185
13.5.1 Effect on Fast Virus Growth 186
13.5.2 Effect on Slow Virus Growth 188
13.6 Summary of Model Properties 189
13.7 Properties of the Internal Equilibrium 189
13.7.1 Fast Virus Growth 190
13.7.2 Slow Virus Growth 191
13.8 Summary 193
References 194

14 Spatial Oncolytic Virus Dynamics 195
14.1 Introduction 195
14.2 A Spatially Explicit Agent-based Model of Oncolytic Virus Dynamics 196
14.3 Initial Virus Growth Patterns 197
14.4 Growth Patterns and the Extinction of Cells 199
14.4.1 Small Grid 201
14.4.2 Analytical Insights: Global Outcome can be Predicted by the Local Dynamics 202
14.4.3 Large Grid 205
14.5 Experimentally Observed Patterns of Virus Spread 207
14.6 Summary 211
References 212

15 Oncolytic Viruses and the Eradication of Drug-Resistant Tumor Cells 215
15.1 Introduction 215
15.2 The Model 216
15.3 Dynamics in the Absence of Mutations 218
15.4 Effect of Mutations 219
15.5 Summary 222
References 223

Index 225